Date: 2011-04-05
Type of information: Capital increase
Company: Cellectis (France)
Investors: Caisse des dépôts (France)
Amount: €12 million
Funding type: capital increase
Planned used: Ectycell is dedicated to the industrial development of induced Pluripotent Stem (iPS 1) cells. Ectycell is a sublicensee of Cellectis for various intellectual property usage rights, including those relating to iPS cell technology, under license from iPS Academia Japan. The agreement with Caisse des Dépôts is part of an ambitious program launched by Ectycell and dedicated to the development, industrial production and marketing of iPS cells. This program will be run with the support of Oseo, a French public structure that provides financial support for innovative French companies. The first commercial offers will be available in the coming months. They will provide unprecedented solutions to current techniques in terms of assessment of toxicity and efficacy of new drugs and cosmetic products.
Others: Cellectis' subsidiary Ectycell has signed an agreement with the Caisse des Dépôts for a planned capital investment of €12M, in two steps, reserved in equal parts to Cellectis and Caisse des Dépôts. This agreement should start no later than January 31, 2012, and is subject to the achievement of certain technical conditions. Following this investment, Cellectis is set to hold about 75% of the capital stock and voting rights of Ectycell, the rest being held by Caisse des Dépôts.
Therapeutic area: Technology - Services
